Brainomix
PrivateLast Round
Series C
Extension
Feb 24, 2026
Total Funding Raised
$57.7M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Brainomix operates in Healthcare & Life Sciences and is based in Oxford. Its latest recorded funding round was a Series C Extension round in February 2026.
Brainomix is a medical technology company that provides an AI-powered platform with imaging biomarkers to assist clinicians with diagnosis and treatment decisions for stroke, lung fibrosis, and cancer.
Sector
Healthcare & Life Sciences
Verticals
Medical Imaging, Medical AI, Healthcare Analytics, Computer Vision, Vertical SaaS
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Brainomix Comparables
Compare Brainomix with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nicolab | 88% | |
| RapidAI | 86% | |
| Cercare Medical | 84% |
For institutional investors. Book with your work email.
Brainomix Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Feb 24, 2026 | ||||
| Series C | Mar 18, 2025 | ||||
| Grant | Oct 12, 2023 | ||||
| Series B | Dec 16, 2021 | ||||
| Grant | Sep 8, 2020 | ||||
Series A | Apr 3, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Brainomix Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| Boehringer Ingelheim | Series C |
| IP Group | Series C |
| Hostplus Superannuation Fund | Series C, Series C Extension |
| NHSX | Grant |
| IP Group Australia | Series C Extension |
| Boehringer Ingelheim Venture Fund | Series A, Series B, Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 21, 2026
Monthly visitors grew 30% MoM, reaching 10.8K.
- Apr 15, 2026
Monthly visitors increased 36% MoM to 11.5K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withOct 14, 2026
Brainomix partners with Pulmonary Fibrosis Foundation to bring patient and caregiver perspectives into research on how AI-powered lung imaging supports care for pulmonary fibrosis and other fibrotic interstitial lung diseases in England and Illinois on Oct 14th '26.
- attends_eventSep 8, 2026
Brainomix presents positive results from AI-driven quantitative HRCT analysis in Endeavor BioMedicines’ Phase 2a taladegib trial at the European Respiratory Society (ERS) Conference in Spain on Sep 8th '26.
- partners_withSep 8, 2026
Brainomix and Endeavor BioMedicines partner on a post-hoc analysis of AI-powered quantitative imaging outputs for clinical trials and present positive results from taladegib's Phase 2a idiopathic pulmonary fibrosis trial at the ERS Conference in Spain on Sep 8th '26.
- attends_eventAug 25, 2026
Brainomix plans to present five new studies at ERS Congress demonstrating the potential of quantitative CT in interstitial lung disease.
For institutional investors. Book with your work email.
Brainomix Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Brainomix's valuation, stock price, and market status.
Is Brainomix a public or private company?
Brainomix is a private company.
What is the current stock price of Brainomix?
Brainomix is a private company, so its shares have no public market price. Caplight tracks Brainomix's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Brainomix worth (valuation)?
Valuation information for Brainomix is not publicly available.
Can I buy Brainomix stock?
Brainomix shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Brainomix's last funding round?
Brainomix's most recent funding round was Series C Extension on February 24, 2026.
Who are the main investors in Brainomix?
Key investors in Brainomix include Boehringer Ingelheim, Hostplus Superannuation Fund, Boehringer Ingelheim Venture Fund, Parkwalk Advisors.
Will Brainomix IPO soon?
No public IPO plans have been announced for Brainomix.
How can I track Brainomix secondary market activity?
Caplight tracks bids, offers, and trades in Brainomix's shares on secondary markets.